

Microbiological and Analytical Evaluation of Semi-Solid Formulations of Doxycycline Hyclate under Accelerated Stability Conditions

Ola Aasi*¹  , Youssef Alahmad¹  , Mustafa Beesh²  , Amin Swed³  

¹ Department of Pharmaceutical Chemistry and Drug Control, Collage of Pharmacy, Al-Baath University, Homs, Syria.

² Department of Pharmaceutics and Pharmaceutical Technology, Collage of Pharmacy, Al-Andalus University, Tartous, Syria.

³ Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Baath University, Homs, Syria.

*Corresponding Author.

Received 02/04/2023, Revised 02/10/2023, Accepted 04/10/2023, Published Online First 20/02/2024,
Published 01/09/2024



© 2022 The Author(s). Published by College of Science for Women, University of Baghdad.

This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Doxycycline Hyclate (DOX) is a broad-spectrum antibiotic that belongs to the tetracycline family. It has been widely used in the treatment of several inflammatory diseases, and is considered the first-line therapy in the management of moderate to severe cases of acne. In this research, Doxycycline was formulated in four semi-solid formulations (F1 and F2 as Gels, F3 and F4 as ointments), then these formulations were subjected to accelerated stability conditions for three months. The formulations were evaluated using microbiological and analytical methods after one and three months. Agar well diffusion method was used as a microbiological method to screen the antibacterial activity of semi-solid formulations against two types of bacteria, *Staphylococcus Aureus* and *Pseudomonas Aeruginosa*. HPLC was used as an analytical method for the quantitative and qualitative determination of these formulations. A comparison between a microbiological assay and analytical assay was achieved to evaluate the activity. The results showed that the ointment formulations were more stable than gel formulations since the percentages of drug were 91%, 93% at 25 °C after one month for formulations (F3, F4) against 90%, 65% for formulations (F1, F2) respectively. Antibacterial activity results showed that formulation F4 had the highest zone of inhibition, which is 31mm for *S.aureus* and 26 mm for *P. aeruginosa* after storing it for three months at 25°C. The formulations were still effective despite the chemical degradation of doxycycline, this effectiveness returns to the fact that degradation products could still have active structural parts responsible for the antibacterial activity.

Keywords: Accelerated stability study, Antibacterial activity, Doxycycline Hyclate, HPLC, Semi-solid formulation.

Introduction

Doxycycline (DOX) is a broad-spectrum bacteriostatic antibiotic, that belongs to the second-generation tetracyclines family¹ Fig. 1. Doxycycline hyclate is reversibly bound to the 30S

ribosomal subunit inhibiting the protein synthesis². DOX is more effective than other tetracyclines against a wide variety of microorganisms including the enterococci and various anaerobes, plasmodium

and protozoa³. It also has antibacterial properties against *P. aeruginosa* and *S.aureus* which are considered the most common bacteria causing chronic wound and soft tissue infections, with inhibition zone between 13.66±1.69 mm to 32.00 mm against *S. aureus* and 4.00± 1.63 to 12.33±0.94 mm for *P. aeruginosa*⁴. According to the American Academy of Dermatology, oral tetracyclines (doxycycline and minocycline) are considered the first-line therapy for the treatment of moderate-to-severe acne vulgaris⁵.

At present, doxycycline is administered orally but it is associated with systemic side effects such as oesophageal ulceration, photosensitivity and systemic allergic reactions^{6,7}. Systemic side effects might be circumvented by topical preparations which have the advantage of delivering the active ingredient more directly to the site of action avoiding the first-pass metabolism and selectively targeting microorganisms in the affected area^{8,9}.

Stability testing may provide evidence to assess the quality of a drug substance, the product variations over time and the influence of environmental factors such as temperature and humidity^{10,11}. DOX has a poor stability profile and could be degraded by hydrolysis and epimerization, producing several degradation products¹². Keto-enol tautomerism has also been described in the degradation of DOX¹³. It has been reported that these derivative degradation products of Doxycycline might be more active and/or toxic than their parents¹⁴. In the literature, the stability of doxycycline and other tetracyclines has been studied in water, in a non-aqueous solvent¹³, in a variety of formulations including suspensions, slow release systems, tablets and capsules¹⁰, while stability studies in topical formulations were rare. There were many attempts to develop stable topical

Materials and Methods

Doxycycline Hyclate (DOX)(purity≥97) was obtained from (Hebei Dongfeng, China). Carbopol 940 was purchased from (Speciality, UAE). HPMC E6 was purchased from (Shan-dong, China). Propyl paraben and methyl paraben were purchased from (Salicylate, India). Propylene glycol and Vaseline were purchased from (Noor orchid, India). TEA (Tri Ethanol Amine) was purchased from (Merck, USA).

formulations of tetracycline. (Gupta et al. ...2021) developed and formulated doxycycline hydrochloride hydrogels employing various polymers for wound healing applications and investigated their stability¹⁵. In another work, (Soni et al. ...2021) prepared and evaluated bigel of doxycycline hyclate for the effective treatment of acne using Carbopol 940 to prepare hydrogel phase whereas span-60 and olive oil for the oleogel phase¹⁶. In addition, a gel of doxycycline (Atridox®) has been developed to treat the chronic adult periodontitis, the product is composed of a two syringe mixing system. Syringe A contains the delivery system (flowable polymeric formulation PLA), while syringe B contains doxycycline. Upon contact with the crevicular fluid, the liquid product solidifies leading to control of the drug release for 7 days¹⁷.

The aim of this study was to prepare and evaluate the stability of doxycycline in different topical formulations. In addition, a comparison was performed between the amount of doxycycline measured chemically by the HPLC method, and the antibacterial activity of doxycycline carried out microbiologically by the Agar well diffusion method after the exposure of the formulations to accelerated stability conditions.




Figure 1. The structural formula of Doxycycline Hyclate¹.

Vit E and BHT (butylated hydroxyl toluene) were purchased from (BASF, USA). And lastly Ethanol 96% was purchased from (Sari- Syria).

Preparation of semi-solid Formulations

Four semi-solid formulations with different physicochemical properties were prepared (hydrogel

F1, organo gel F2, hydrophobic ointment F3, and hydrophobic ointment with additive antioxidant F4). Table 1 illustrates the compositions of the four formulations and the percentage of each component. Hydrogels were prepared by dispersing carbopol and HPMC E6 in water (F1)/water and alcohol (F2) with stirring and heating to 60°C. Doxycycline, methyl paraben and propyl paraben were dissolved in

glycerine and propylene glycol, then were added to the carbopol gel. pH was adjusted to 5-7 using triethanolamine (TEA). The ointment formulations were prepared by melting vaseline, paraffin oil and BHT at 70°C. After cooling the previous mixture, doxycycline was suspended and mixed with Vit E(F4) using a colloid mill.

Table 1. Composition of formulations and the percentage of each component (%).

Component	F1	F2	F3	F4
	Hydrogel	Organogel	Hydrophobic Ointment	Hydrophobic ointment
	W/W%	W/W%	W/W%	W/W%
Doxycycline Hyclate	0.1	0.1	0.1	0.1
Carbopol 940	0.5	1.25	--	--
HPMC E ₆	0.7	0.7	--	--
Methyl paraben	0.2	0.2	--	--
Propyl paraben	0.5	0.5	--	--
Glycerin	15	2.5	--	--
Propylene glycol	15	7.5	--	--
Ethanol 96%	--	67.3	--	--
Distilled water	67.35	19.5	--	--
TEA	0.65	0.45	--	--
Vit E	--	--	--	0.9
BHT	--	--	0.01	0.1
Vaseline	--	--	96.89	95.9
Paraffin oil	--	--	3	3

Accelerated stability study

After filling the formulation in aluminum containers, a number of prepared formulations were incubated under three different conditions: In the first chamber, the incubation was carried out at 25°C and 40% RH, in the second chamber (30°C, 60% RH), and in the third chamber, (40°C, 75%RH). The formulations were evaluated at three time periods, immediately at the beginning of the procedure, after one and three months, in terms of color, appearance, determination of the content and antibacterial activity.

Chemical assay

High performance liquid chromatography analysis was carried out for the determination of drug content using Shimadzu HPLC equipped with a UV detector, at 40°C using a 250×4.6 mm, 5 mm particle size reversed phase C18 column, Hypersil ODS. The mobile phase employed was a mixture of buffer (5 ml of TEA was taken and dissolved in 500 ml volumetric flask containing distilled water and adjusted the pH to 3.5 using phosphoric acid) and methanol at a volume ratio of (20:80) at a flow rate

of 1.3 ml/min. 2g of each formulation F1 and F2 were dissolved in 100 ml of HCl 0.1N (the concentration is 20 µg/ml). For F3 and F4, 2g of ointment was mixed with 30 ml Hexane and diluted with HCl 0.1N to 100 ml in a separation funnel, then the acidic part was extracted (with a concentration of 20 µg/ml). The HPLC method was developed and validated in-house. The percentage of drug was calculated by the following Eq. 1:

$$\text{Percentage of DOX in formulation \%} = \left(\frac{\text{The area under the curve of sample solution during stability study}}{\text{the area under the curve of sample solution at } t=0} \right) * 100 \dots\dots 1$$

Antibacterial assay

The Agar well diffusion method was used to screen the antibacterial activity of semi-solid formulations against two types of bacteria, which are Gram-positive bacteria (*Staphylococcus aureus*) and Gram-negative bacteria (*Pseudomonas Aeruginosa*)^{18, 19}. Bacterial suspensions were pre-cultured in Mueller Hinton broth (MHB) overnight in a rotary shaker at 37°C. Afterward, each strain was adjusted at a

concentration of 1.5×10^8 colony-forming unit (CFU)/mL using 0.5 McFarland standard. Trypton Soya Agar (TSA) medium was prepared and autoclaved at 121°C for 20 minutes. Four Petri plates containing TSA medium were cultured with $100\ \mu\text{L}$ of *S. aureus* bacterial suspension while the other four plates were cultured with $100\ \mu\text{L}$ of *P. aeruginosa* bacterial suspension. In order to prepare a solution of formulation at a concentration of $100\ \mu\text{g}/\text{ml}$, 5g of each formulation F1 and F2 were dissolved in 50 ml of HCl 0.1N. For F3 and F4, 5g of each ointment was mixed with 25 ml Hexane and 25 ml HCl 0.1N in a separation funnel and the acidic extract was taken. Each Petri plate containing TSA medium was cultured with *S. aureus*. Five wells with a diameter of 7 mm were punched in each plate with a sterile cork borer. The first well was for F1 solution, the

second for F2 solution, the third for F3 solution, the fourth well for F4 solution, and the last well for the Doxycycline solution ($100\ \mu\text{g}/\text{ml}$) was placed as a control. The same procedures were repeated in the plates cultured with *P. aeruginosa*, this test was carried out for all the samples which were incubated in the stability conditions mentioned previously. Later, all plates were incubated in the incubator at 37°C for 24 hrs. The anti-bacterial activity of formulations was determined by measuring the diameter of the inhibition zone and calculated as a percentage according to the following Eq. 2:

The percentage of inhibition zone = [The diameter of the inhibition zone of formulation (cm) during stability stability/ the diameter of the inhibition zone of control (cm)] * 1002

Results and discussion

Characteristics of formulations during accelerated stability study

The physiochemical properties of the prepared formulations should be evaluated to obtain a good formulation that meets the requirements. The organoleptic tests are considered crucial parameters of the quality and stability of the product, so failure of these tests can result in rejection of the preparation. The results showed that the ointment formulations F3, F4 are the most acceptable, they have a greasy feel, an oily smell and a yellow color which returns to the original color of doxycycline. Severe color changes were observed in formulations F1, F2 as it returned from yellow to dark-yellow and brown Fig. 2, while the color change was less remarked in formulation F4, that might be explained by its content of vitamin E as an additive antioxidant Table 1. Color change in F1 and F2 could be attributed to the negative effect of high temperature in addition to the presence of aqueous medium in these formulations, that induce the oxidation of phenolic groups into colored quinones compounds^{20, 21}. No change was observed in the consistency of the prepared formulations during the stability period.




Figure 2. color change during stability period (3 months, 25°C), for F1, F2, F3 and F4.

Chemical assay

The percentage of drug content during the stability study was determined for the four topical formulations Table 2. The results showed a decrease in the percentage of DOX in all prepared formulations during the stability studies. Although the ICH recommends studying the accelerated stability for 6 months, in our research, it was conducted for only 3 months because the amount of Dox was reduced to less than 55%.

The ointment formulations (F3, F4) were more stable than gel formulations (F1, F2). The percentages of drug were 91% and 93% at 25°C after one month for ointment formulations (F3, F4) against 90% and ,65% for gel formulations (F1, F2) respectively. This could be interpreted by that F1 and F2 have aqueous medium that is preferable for epimerization, hydrolysis, deamidation and decarbonylation reactions. This has been recently reported by Bin yang et al. ²², who found that DOX in aqueous medium and high temperature tends to degrade and is subjected to different degradation pathways Fig. 3. In comparison between the ointment formulations F3 and F4, the result revealed that F4 is more stable than F3 formulation, this is likely related to the positive effect of the combination of two antioxidants

(vitamin E and BHT) which could enhance the stability and reduce the oxidation processes of doxycycline. However, the alcoholic formulation F2 was the least stable among the other formulations although it contained small amount of water, the percentage of DOX reached 35.5% after one month of incubation at 40°C. The reason for this is not clear but it might be related to the low viscosity of alcoholic formulation F2 which could be affected by three factors: the effect of decreased pH on the rheology of Carbopol during stability study and led to a weak gel matrix ²³, in addition to the low viscosity of Ethanol itself, and the low percentage of glycerin and propylene glycol, so these factors effect on the viscosity of formulation F2 and led to an increase in the chemical reactivity of Doxycycline ²⁴. Fig. 4 shows the chromatograms of two formulations; F2 and F4. The F2 chromatogram showed peaks that might return to the degradation products, with a decrease in the DOX content after one month, thus making the F2 formulation the least stable formulation. Whereas the F4 chromatogram showed fewer degradation product peaks especially after 1 month without a significant decrease in DOX content and this made it considered the most stable formulation.





Figure 3. Proposed transformation pathways of doxycycline hydrolysis ²².

Table 2. Percentage of DOX in formulations during accelerated stability study.

Temperature	T=0		After one month		After three months	
	25°C	25°C	40°C	25°C	40°C	40°C
F1	99	90	71	71	23	
F2	94.4	65	35.5	40	20	
F3	94.6	91	75	77	40	
F4	95	93	77	80	55	






Figure 4. Chromatograms of the formulations; F2 and F4 at different conditions of time and temperature

Antibacterial activity

The antibacterial activity of the drug was determined by measuring the diameter of inhibition zone. The results in Table 3, Fig. 5 showed that the formulation F4 had the highest zone of inhibition with 31 mm and 26 mm diameters for *S.aurues* and *P.aeruginosa* respectively, after storing the formulations for three months at 25°C. This result also accords with earlier study⁴ which found that DOX is more sensitive to *S.aurues* than *P.aeruginosa*. It's interesting to note that this result was in the t=0, but during stability study, the formulations were more sensitive against

P.aeruginosa than *S.aurues*. This might be related to the antibacterial activity of degradation products formed during stability study. However, all formulations have the diameter of inhibition zone larger than 80% for both types of bacteria after stability study at 40°C for 1 month except F2 formulation which has inhibition zone diameter of about 65% for *S.aurues*. On the other hand, the diameter of inhibition zone under the same conditions after 3 months was larger than 55% for both types of bacteria except F2 which was still active for about 40%. As a result, we could confirm that the formulation F2 has the smallest diameter of inhibition zone towards both types of bacteria, and the formulation F4 has the largest diameter. The comparison between the inhibition zone as a percentage and the concentration of doxycycline was shown in Table 4. This comparison revealed that despite of decrease in concentration of DOX with time, all formulations were still microbiologically effective. Chemically, the ointment formulation F4 was the most stable formulation as it kept about 55% of DOX after storing at 40°C for three months. But biologically, this decrease in concentration was not accompanied by the same decrease in the antibacterial activity, as it was estimated to be about 85%. The same issue also occurred in gel formulations F1, F2, the remaining concentration of the active substance was 23% and 20% respectively, while these formulations remained biologically effective at about 75%, 65% against (*P.aeruginosa*) and 56%, 40% against (*S.aurues*). We can attribute this decrease in the microbiological activity and the difference in percentage between the two types of bacteria to the effect of degradation on the active structural site responsible for antibacterial activity. According to Zhong SF et al²², the possibility of isomerization occurrence at C12 led to dissociate the B ring, and influence on the sequence of naphthacin rings which play an important role in antibacterial activity. Furthermore, the possibility of deamidation occurrence at C2 site leads to a decrease in biological activity. The potential of epimerization at C4 site affects the antibacterial efficacy, especially toward Gram-negative bacteria. Also the presence of enol-keton group at the C11-C12 site contributes to enhancing the therapeutic efficacy, when hydroxylation occurs, the enol group will be lost. So the degradation will occur at one of previous active sites could give degradation products with different antibacterial properties. Moreover, the result of chemical analysis will give a decrease in the

concentration values as a result of the degradation in the structure of doxycycline. Therefore, the antibacterial activity of the formulation was still effective despite the degradation of doxycycline and the physical degradation of formulation, this effectiveness is due to the degradation products which still have the active structural parts responsible for antibacterial activity.

Table 3. Percentage of inhibition zone of formulations (%).

S.aurues							
	Initial	1 month			3 months		
		25°C	25°C	30° C	40°C	25°C	30° C
F1	96	92	92	88	90	72	56
F2	97	96	88	65	80	50	40
F3	92	88	85	81	86	80	70
F4	96	94	93	90	92	84	85

P. aeruginosa							
	Initial	1 month			3 months		
		25°C	25°C	30° C	40°C	25°C	30° C
F1	96	92	90	89	85	80	75
F2	100	93	86	80	75	70	65
F3	100	98	95	90	92	92	80
F4	98	96	95	92	92	92	85

Table 4. Comparison between the chemical assay (HPLC) and the percentage of inhibition zone during stability study.

	Antibacterial Activity (%)		HPLC Assay (%)
	P. aeruginosa	S.aurues	3months/ 40°C
	3months/40°C	3months/40° C	
F1	75	56	23
F2	65	40	20
F3	80	70	40
F4	85	85	55




Figure 5. Inhibition zone of F4 formulation against S. aureus and P. aeruginosa at different stability conditions

Conclusion

As a result of the accelerated stability study of Doxycycline semi-solid formulations, ointment formulations are better than gel formulations in terms of color, appearance, drug content and antibacterial activity. The concentration of doxycycline was decreased with time by increasing the temperature, while antibacterial activity was relatively conserved

against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. The chemical degradation does not necessarily reflect the antibacterial activity due to the similarity in structure of the degradation products to the parent compound, in addition to having antibacterial properties even though the formulations are physically destroyed.

Acknowledgment

The authors are pleased to thank the staff of Al-Baath University and College of Pharmacy for supporting

them in this research. We are also grateful to Medico Pharmaceutical Industries for their help and support.

Authors' Declaration

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are ours. Furthermore, any Figures and images, that are not ours, have been included with the necessary permission for re-publication, which is attached to the manuscript.
- Authors sign on ethical consideration's approval.
- Ethical Clearance: The project was approved by the local ethical committee at University of Al-Baath.

Authors' Contribution Statement

O.A., Y.A., M.B and A.S contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.

References

1. Kashani-Asadi-Jafayeeeri F, Hadjizadeh A. Niosome-encapsulated Doxycycline Hyclate for Potentiation of Acne Therapy: Formulation and Characterization. *Pharm Nanotechnol.* 2022; 10(1): 56-68. <https://doi.org/10.1101/2021.09.28.462256>
2. Aliah A, Oktaviani WW, Erdiana AP, Dwipayanti KS, Utami RN, Permana AD. Enhanced skin localization of doxycycline using microparticles and hydrogel: effect of oleic acid as penetration enhancer. *Pharmaciana.* 2021; 11(2): 239-250. <http://dx.doi.org/10.12928/pharmaciana.v11i2.21044>
3. Patel RS, Parmar M. Doxycycline Hyclate.. In: *StatPearls.* Treasure Island (FL). National library of medicine. NCBI. StatPearls Publishing; 2023.
4. Borse VA, Gangude AB, Deore AB. Formulation and evaluation of antibacterial topical gel of doxycycline hyclate, neem oil and tea tree oil. *Indian J Pharm Educ Res.* 2020; 54(1): 206–212. <https://doi.org/10.5530/ijper.54.1.24>
5. KirciK L, Weiss JS, Del Rosso JQ, Stakias V, London A, Keynan R, et al. Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris. *J Clin Aesthet Dermatol.* 2020; 13(4): 14–21.
6. Gugleva V, Titeva S, Rangelov S, Momekova D. Design and in vitro evaluation of doxycycline hyclate niosomes as a potential ocular delivery system. *Int J Pharm.* 2019;567: 11843.<https://doi.org/10.1016/j.ijpharm.2019.06.022>
7. Smith R, Russo J, Fiegel J, Brogden N. Antibiotic delivery strategies to treat skin infections when innate antimicrobial defense fails. *Antibiotic.* 2020; 9(2): 1-25. <https://doi.org/10.3390/antibiotics9020056>
8. Cheng T, Tai Z, Shen M, Li Y, Yu J, Wang J, et al. Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System. *Pharmaceutics.* 2023; 15(8):2165. <https://doi.org/10.3390/pharmaceutics15082165>
9. Marco AD, Giuffrida R, Bonamonte D, Conforti C, Barlusconi C, Foti C, et al. Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects. *Dermatol Ther.* 2020; 33(6). <https://doi.org/10.1111/dth.13824>
10. Montejo O, Modamio P, Lastra CF, Segarra I, Mestorino N, Mariño EL. Twenty-Week Solid-State Stability Study of Combined Doxycycline, Trimethoprim and Sulfamethoxypyridazine Formulations after Extemporaneous Preparation for Veterinary Use. *Pak Vet J.* 2015; 35(1): 111-113.
11. González-González O, Ramirez OL, Ramirez BI, O'Connell P, Ballesteros M, Torrado JJ, et al. Drug Stability: ICH versus Accelerated Predictive Stability Studies. *Pharmaceutics.* 2022; 14(11): 2324. <https://doi.org/10.3390/pharmaceutics14112324>
12. Loftin KA, Surampalli R, Adams CD, Meyer MT. Effects of ionic strength, temperature, and pH on degradation of selected antibiotics. *J Environ Qual.* 2008; 37(2): 378–386. <https://doi.org/10.2134/jeq2007.0230>
13. Jutglar M, Foradada M, Caballero F, Hoogmartens J, Adams E, Influence of the solvent system on the stability of doxycycline solutions. *J Pharm Biomed Anal.* 2018; 159: 60-65.<https://doi.org/10.1016/j.jpba.2018.06.054>
14. Li WN, Bao YY, Zhou QX, Degradation pathways and main degradation products of tetracycline antibiotics: research progress. *Ying Yong Sheng Tai Xue Bao.* 2012; 23(8): 2300-2308.

15. Gupta NV, Shanmuganathan S, Kanna S, Sastr KT. A 23factorial design for formulation and development of doxycycline hydrochloride in situ gel forming solution for wound healing application. *Int J App Pharm*, 2021; 13(3): 221-232. <https://doi.org/10.22159/ijap.2021v13i3.39696>
16. Soni K, Gour V, Agrawal P, Haider T, Bakshi A, Soni V. Carbopol-olive oil-based bigel drug delivery system of doxycycline hyclate for the treatment of acne. *Drug Dev Ind Pharm* 2021; 47(6): 954-962. <https://doi.org/10.1080/03639045.2021.1957916>
17. Javali MA, Vandana KL. A comparative evaluation of atrigel delivery system (10% doxycycline hyclate) Atridox with scaling and root planing and combination therapy in treatment of periodontitis: A clinical study. *J Indian Soc Periodontol*. 2012; 16(1): 43-8. <https://doi.org/10.4103/0972-124x.94603>
18. Fayyadh AA, Essa AF, Batros SS, Shallal ZS. Studying the Crystal Structure, Topography, and Anti-bacterial of a Novel Titania (TiO₂ NPs) Prepared by a Sol-gel Manner. *Baghdad Sci J*. 2019; 16(4): 0910 <https://doi.org/10.21123/bsj.2019.16.4.0910>
19. Toma JJ, Aziz FH. Antibacterial Activity of Three Algal Genera against some Pathogenic Bacteria. *Baghdad Sci J*. 2023; 20(1): 0032. <https://doi.org/10.21123/bsj.2022.6818>
20. Meetam P, Limmatvapirat C, Krongrawa W, Limmatvapirat S, Pongnimitprasert N. Formulation and evaluation of gels containing coconut kernel extract for topical application. *Asian J Pharm Sci*. 2018; 13(5): 415-424. <https://doi.org/10.1016/j.ajps.2018.01.005>
21. Salas AL, Uriburu FMC, Zampi C, Arias M. Hydroalcoholic gel with Argentine propolis: the potential for antimicrobial and antioxidant activities, stability evaluation, and in vitro phenolic release. *J Apic Res*. 2020; 59(5): 735-743. <https://doi.org/10.1080/00218839.2020.1790791>
22. Zhong SF, Yang B, Xiong Q, Lan ZG, Ying GG. Hydrolytic transformation mechanism of tetracycline antibiotics: Reaction kinetics, products identification and determination in WWTPs. *Ecotoxicol Environ Saf*. 2022; 229: 113063. <https://doi.org/10.1016/j.ecoenv.2021.113063>
23. Maslii Y, Ruban O, The Influence of pH Values on the Rheological, Textural and Release Properties of Carbomer Polacril® 40P-Based Dental Gel Formulation with Plant-Derived and Synthetic Active Components. *Molecules*. 2020; 25 (21): 5018. <https://doi.org/10.3390/molecules25215018>
24. Hinks ML, Brady MV, Lignell H, Song M, Grayson GW, Bertram AK, et al. Effect of viscosity on photodegradation rates in complex secondary organic aerosol materials. *Phys Chem Chem Phys*. 2016; 18: 8785-8793. <https://doi.org/10.1039/C5CP05226B>

التقييم التحليلي والميكروبيولوجي لتحضيرات صيدلانية نصف صلبة من الدوكسيسيكليين هايكلتات تحت شروط الثبات المسرع

علا عاصي*1، يوسف الأحمد¹، مصطفى بيش²، أمين سويد³

¹ قسم الكيمياء الصيدلانية والمراقبة الدوائية، كلية الصيدلة، جامعة البعث، حمص، سوريا.

² قسم الصيدلانيات والتكنولوجيا الصيدلانية، كلية الصيدلة، جامعة الأندلس، طرطوس، سوريا.

³ قسم الصيدلانيات والتكنولوجيا الصيدلانية، كلية الصيدلة، جامعة البعث، حمص، سوريا.

الخلاصة

الدوكسيسيكليين هايكلتات هو مضاد حيوي واسع الطيف ينتمي لعائلة التتراسيكلينات، يستخدم بشكل واسع في معالجة العديد من الأمراض الالتهابية، ويعتبر الخط العلاجي الأول في تدبير الحالات المتوسطة إلى الشديدة من حب الشباب. تم في هذا البحث صياغة أربع صيغ نصف صلبة للدوكسيسيكليين (F2, F1) كصيغ هلامية، F3, F4 كصيغ مرهمية، ثم عرّضت الصيغ السابقة إلى شروط ثبات مسرعة في حاضنات الثبات لمدة ثلاثة أشهر. تم تقييم الصيغ المحضرة باستخدام طرق ميكروبيولوجية وتحليلية وذلك خلال شهر وثلاثة أشهر. استخدمت طريقة الانتشار على الأغار لتقييم الفعالية المضادة للجراثيم وذلك على نوعين من الجراثيم، العنقوديات المذهبة والزائفة الزنجارية. بينما استخدم HPLC كطريقة تحليل كمية وكيفية لمقايضة الصيغ. أجريت مقارنة بين نتائج المقايضة الميكروبيولوجية والمقايضة التحليلية لتقييم الفعالية. أظهرت النتائج أن الصيغ المرهمية F3, F4 أكثر ثباتاً من الصيغ الهلامية F1, F2، حيث بلغت النسبة المئوية للدوكسيسيكليين 93% و91% للصيغ F3, F4 على التوالي وذلك عند الحفظ بدرجة حرارة الغرفة بعد شهر واحد. بينما بلغت النسبة 90% و65% للصيغ الهلامية F2, F1 عند الحفظ في نفس الشروط السابقة. أظهرت نتائج قياس الفعالية المضادة للجراثيم أن الصيغة المرهمية F4 امتلكت أكبر قطر تثبيط جرثومي ويقدر بحوالي 31 ملم للعنقوديات المذهبة و26 ملم للزوائف الزنجارية وذلك بعد حفظ الصيغة لمدة ثلاثة أشهر عند درجة الحرارة 25°C. وبالتالي حافظت الصيغ على فعاليتها على الرغم من التخرب الكيميائي البيولوجي للحاصل للدوكسيسيكليين. تعود هذه الفعالية إلى حقيقة أن نواتج التخرب لا تزال محافظة على الموقع البيولوجي الفعال والمسؤول عن إعطاء الفعالية المضادة للجراثيم.

الكلمات المفتاحية: دراسة ثبات مسرعة، الفعالية المضادة للجراثيم، دوكسيسيكليين هايكلتات، الكروماتوغرافيا السائلة عالية الأداء، صيغ صيدلانية نصف صلبة.